MDSpire - Summary
Clinical Guidelines
FDA & Government News

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for the treatment of adult patients with relapsed or re...

Share

On March 5, 2026, the FDA granted full approval for teclistamab (Tecvayli) combined with daratumumab hyaluronidase-fihj for treating adult patients with relapsed or refractory multiple myeloma who have undergone at least one prior therapy, including a proteasome inhibitor and an immunomodulatory agent. This approval converts teclistamab's previous accelerated monotherapy approval for patients with more extensive prior treatments. Key trials demonstrated significant efficacy and safety, with a notable focus on progression-free and overall survival metrics.

Original Source(s)

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

  • by The ASCO Post Staff

  • March 24, 2026

Related Content

Stanford Names Leader for Drug Development and Precision Oncology

Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In thi...

In Celebration of a Decades-Long Journey of Discovery and Innovation

On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds th...

Integrative Oncology Scholars Program

Applications are now being accepted for the 2026 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program at the University of Michigan in Ann Arbor (https://sites.google.com/vie...